Harmony Biosciences Projects 21.4% Sales Growth and Reports 7.2% Earnings Surprise
Harmony Biosciences holds a Zacks Rank #1 with a Value Score A and boasts a trailing four-quarter earnings surprise of 7.2%. Consensus estimates project 21.4% sales growth and 25.9% EPS growth this fiscal year, while shares have climbed 4.6% over the past year.
1. Zacks Screening and Valuation Metrics
Harmony Biosciences was selected among four value stocks with a Zacks Rank #1 and a Value Score A, reflecting strong price-to-cash flow metrics relative to peers.
2. Projections and Earnings Surprise
The company recorded a trailing four-quarter earnings surprise of 7.2% and carries consensus estimates forecasting 21.4% sales growth and 25.9% EPS growth for the current financial year.
3. Share Performance
Shares of Harmony Biosciences have increased by 4.6% over the past year, aligning with its favorable value metrics and growth projections.
Related News
GOOGL
Alphabet Executes Record Yen Bond Sale as Google Secures 9.7 GWh AI Storage Contracts
GOOGL•
GOOG
Google, Blackstone Launch $5B AI Cloud JV with 500MW Capacity by 2027
GOOG•
DE
Menon Bearings Posts 23% Revenue Gain, 51 New Parts for Deere Supply
DE•
GOOG
OpenAI Eyes Fall IPO After Lawsuit Win, Battling $900B Anthropic Rival
GOOG•
GOOG
Google Secures Tens of Thousands of MWh Storage as U.S. Energy Storage Hits Q1 Record
GOOG•
Sources
F